DUBLIN--(BUSINESS WIRE)--The "Global Gene Therapy Market Analysis & Forecast to 2022" report has been added to ResearchAndMarkets.com's offering.
The global gene therapy market is forecast to hit $363 million by 2022.
Strengthened by recent approvals of Kymriah, Yescarta and Luxturna in the US, and a committed European, Japanese and Chinese environment, gene therapy is set to become a significant player in the bio-pharmaceutical industry. The space covers many therapeutic areas specifically, oncology, rare diseases, Parkinson's, HIV, severe combined immuno-deficiencies (SCID) and hemophilia.
Gene therapy is driven by over 2,200 clinical trials globally, with over 55% of this occurring in the US, followed by Europe, Canada and China. Recently, in November 2017, the FDA indicated that gene therapies will now qualify for a fast approval process, which will bring more therapies to market faster. However, the space also has significant challenges, such as manufacturing logistics, reimbursement and its high cost.
Key Topics Covered:
1.0 Introduction
2.0 Gene Therapy: The Basics
3.0 Historic Overview of Gene Therapy
4.0 Gene Therapy Phase III Product Candidates
5.0 Gene Therapy Phase II Product Candidates
6.0 Commercialization, Cost and Warranty of Gene Therapies
7.0 The Strength of Gene Therapy Industry
8.0 Vectors for Gene Delivery
9.0 Clinical Applications of Gene Therapy
10.0 Market Analysis
11.0 Manufacturing of Viral Vectors and Logistics
12.0 Company Profiles
- AGCT
- Abeona Therapeutics LLC
- Amgen
- AnGes MG Inc.
- BioCancell Therapeutic Inc.
- BioMarin Pharmaceutical Inc.
- Copernicus Therapeutics Inc.
- Dimension Therapeutics Inc.
- Editas Medicine Inc.
- Fibrocell Sciences Inc.
- Florida Biologix
- Fondazione Telethon
- Genzyme (Sanofi)
- GlaxoSmithKline
- Glybera
- Medgenics Inc.
- Mirus Bio LLC
- Molecular Therapeutics LLC
- Mologen AG
- NightstaRx Ltd.
- Novartis
- Novasep Process SAS
- ORCA Therapeutics B.V.
- Omnia Biologics Inc.
- Sanofi
- Sarepta Therapeutics Inc.
- Shanghai Sunway Biotech Co. Ltd.
- SiBiono GeneTech Co. Ltd.
- Sirion Biotech GmbH
- Spark Therapeutics Inc.
- Takara Bio Inc.
- Taxus Cardium Pharmaceutical Group Inc.
- Vical Inc.
- Voyager Therapeutics
- Xenon Pharmaceuticals Inc.
For more information about this report visit https://www.researchandmarkets.com/research/c9fmjd/global_gene?w=4
